We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

80 hedge funds and large institutions have $132M invested in Viracta Therapeutics, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

136% more call options, than puts

Call options by funds: $5.78M | Put options by funds: $2.45M

19% more capital invested

Capital invested by funds: $111M → $132M (+$21.4M)

8% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 25

4% less funds holding

Funds holding: 83 → 80 (-3)

16% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 19

Holders
80
Holders Change
-3
Holders Change %
-3.61%
% of All Funds
2.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
23
Reduced
25
Closed
19
Calls
$5.78M
Puts
$2.45M
Net Calls
+$3.33M
Net Calls Change
+$1.32M

Top Buyers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
+$5.47M
2
GPP
Great Point Partners
Connecticut
+$3.8M
3
Goldman Sachs
Goldman Sachs
New York
+$1.11M
4
DCM
Driehaus Capital Management
Illinois
+$1.11M
5
FWM
Frontier Wealth Management
Missouri
+$868K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$4.64M
2
BFA
BlackRock Fund Advisors
California
-$3.34M
3
State Street
State Street
Massachusetts
-$1.79M
4
First Eagle Investment Management
First Eagle Investment Management
New York
-$1.44M
5
GTC
Ghost Tree Capital
New York
-$1.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
PC
26
Polar Capital
United Kingdom
$828K +$696K +1,310 New
Geode Capital Management
27
Geode Capital Management
Massachusetts
$759K +$3.19K +6 +0.5%
SM
28
Sabby Management
Florida
$738K -$75.5K -142 -11%
DA
29
DSC Advisors
Illinois
$677K – – –
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$613K -$1.26M -2,373 -71%
HVC
31
Healthcare Value Capital
New Jersey
$602K – – –
Group One Trading
32
Group One Trading
Illinois
$564K +$211K +397 +80%
CS
33
Credit Suisse
Switzerland
$543K +$402K +756 +727%
BFA
34
BlackRock Fund Advisors
California
$458K -$3.34M -6,294 -90%
NFA
35
Nationwide Fund Advisors
Ohio
$453K +$284K +535 +296%
TCIM
36
TIAA CREF Investment Management
New York
$417K -$129K -242 -27%
Deutsche Bank
37
Deutsche Bank
Germany
$408K +$343K +646 New
TD Asset Management
38
TD Asset Management
Ontario, Canada
$402K – – –
California Public Employees Retirement System
39
California Public Employees Retirement System
California
$351K – – –
COPPSERS
40
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$323K +$272K +511 New
JP Morgan Chase
41
JP Morgan Chase
New York
$301K +$160K +301 +171%
PP
42
Paloma Partners
Connecticut
$278K +$234K +440 New
HCM
43
Highbridge Capital Management
New York
$230K +$91.9K +173 +91%
QSS
44
Quantitative Systematic Strategies
Florida
$196K -$242K -456 -59%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$177K -$386K -727 -72%
WMSA
46
Weiss Multi-Strategy Advisers
New York
$169K +$1.06K +2 +0.8%
Jane Street
47
Jane Street
New York
$160K +$134K +253 New
LP
48
LMR Partners
United Kingdom
$147K +$123K +232 New
CC
49
Caxton Corporation
New Jersey
$144K +$121K +228 New
UBS Group
50
UBS Group
Switzerland
$143K -$706K -1,329 -86%
1
2
3 4

VIRX Hedge Fund Activity: Q2 2015 in Review

80 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2015, worth a combined $132M — up 19% from $111M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of VIRX and 16 opened new positions — a net loss of 3 holders — while 25 trimmed existing stakes and 23 added.

The largest buyer was Farallon Capital Management, opening a new position worth an estimated $5.47M. The largest seller was BVF Inc, exiting entirely with an estimated $4.64M sold.

  • 80 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2015, down from 83 in Q1 2015.
  • Funds reported $132M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2015, up 19% quarter-over-quarter.
  • 16 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2015 and 19 closed out, a net change of -3 holders.
  • The largest Viracta Therapeutics, Inc. Common Stock buyer in Q2 2015 was Farallon Capital Management, an estimated $5.47M added.
  • The largest Viracta Therapeutics, Inc. Common Stock seller in Q2 2015 was BVF Inc, an estimated $4.64M sold.

Based on aggregated 13F filings for Q2 2015.